<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00216411</url>
  </required_header>
  <id_info>
    <org_study_id>A-9B-52120-097</org_study_id>
    <nct_id>NCT00216411</nct_id>
  </id_info>
  <brief_title>Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm</brief_title>
  <official_title>A Prospective Phase IV, Multicentre, Placebo-controlled Study to Demonstrate Changes in the Quality of Life Following DYSPORT Intramuscular Injection in the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess the effect on Quality of Life of two cycles of
      Dysport treatment on post-stroke spasticity of the upper limb. The effect of treatment on
      spasticity and function will also be measured.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">July 20, 2006</completion_date>
  <primary_completion_date type="Actual">July 20, 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quality of life measured using the Assessment of Quality of Life questionnaire (12 question version).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in muscle spasticity assessed on Modified Ashworth Scale (MAS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Modified Motor Assessment Scale</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient disability and carer burden rating scale total score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of the patient identified functional outcome measures (Goal Attainment Scaling)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the degree of pain</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depression rating scale total score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of benefit</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Cerebrovascular Accident</condition>
  <condition>Muscle Spasticity</condition>
  <arm_group>
    <arm_group_label>Dysport</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botulinum toxin type A</intervention_name>
    <arm_group_label>Dysport</arm_group_label>
    <other_name>AbobotulinumtoxinA (DysportÂ®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has suffered a stroke, as defined by the World Health Organisation (WHO)
             criteria, at least 6 months previously.

          -  The patient has a hemiparetic arm and meets minimum score requirements on the Modified
             Ashworth Scale.

          -  The patient has the cognitive and communication ability to participate in the study.

        Exclusion Criteria:

          -  Patients who have received botulinum toxin treatment within the past 120 days.

          -  Contraindication to botulinum toxin treatment.

          -  Patients who are receiving oral anti-spasticity medication and who have had a change
             in dosage of this medication in the month prior to study entry.

          -  Patients who have previously been treated with phenol for their upper limb spasticity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Josephs Hospital</name>
      <address>
        <city>Auburn</city>
        <state>New South Wales</state>
        <zip>2144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caulfield General Medical Centre</name>
      <address>
        <city>Caulfield</city>
        <state>Victoria</state>
        <zip>3162</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

